Showing 4381-4390 of 5659 results for "".
- INTEGUMENT-INFANT to Test Roflumilast Cream in Children Under Twohttps://practicaldermatology.com/news/integument-infant-to-test-roflumilast-cream-in-children-under-two/2475087/Arcutis Biotherapeutics has announced the enrollment of the first participants in its new phase 2 INTEGUMENT-INFANT study focusing on the safety and tolerability of ZORYVE (roflumilast) cream 0.05% in infants with atopic dermatitis (AD).
- Patent Issued for Coya’s IL-2 Technologyhttps://practicaldermatology.com/news/patent-issued-for-coyas-il-2-technology/2474992/Coya Therapeutics has received a new U.S. patent for proprietary methods of producing a highly stable liquid formulation (aldesleukin) of recombinant human interleukin-2 (rhIL-2), according to a press release from the manufacturer.
- LEO Pharma Launches Study of Delgocitinib for PPPhttps://practicaldermatology.com/news/leo-pharma-launches-study-of-delgocitinib-for-ppp/2474972/LEO Pharma announced today the initiation of a phase 2a trial looking at the safety and efficacy of delgocitinib cream in adults with palmoplantar pustulosis (PPP). According to a news release from the manufacturer, the DELTA
- ADA: Dermatologists Need to Lead on Climate Healthhttps://practicaldermatology.com/news/ada-dermatologists-need-to-lead-on-climate-health/2474867/The American Dermatological Association (ADA) has issued its first comprehensive policy statement on climate change, publishing the document in the Journal of Investigative Dermatology.
- EFFISAYIL 2: Spesolimab Associated with Long-Term GPP Reliefhttps://practicaldermatology.com/news/effisayil-2-spesolimab-associated-with-long-term-gpp-relief/2474835/Patients with generalized pustular psoriasis (GPP) experienced sustained symptom control and quality of life (QoL) improvements when treated with spesolimab, according to an analysis of results from the EFFISAYIL 2 trial. Re
- Polypharmacy Issues in Older Patients Concerning but Improvinghttps://practicaldermatology.com/news/Polypharmacy-Issues-Older-Patients-Concerning-Improving/2474817/Geriatric medicine hinges on eight guiding principles, Freba Farhat, MD, said at the ElderDerm 2025 Conference in Washington, DC: life expectancy, multimorbidity, functional status, cognition, mobility, social support, patient preference, and polypharmacy. The last of those factors can sometimes
- ZORYVE Foam Cleared by FDA for Full-Body Psoriasishttps://practicaldermatology.com/news/zoryve-foam-cleared-by-fda-for-full-body-psoriasis/2474798/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis in patients aged 12 and older, according to a press release from the manufacturer.
- Concerto Biosciences Completes Data Collection for Massive Skin Microbiome Interaction Projecthttps://practicaldermatology.com/news/concerto-biosciences-completes-data-collection-for-massive-skin-microbiome-interaction-project/2474768/Concerto Biosciences announced today that it has concluded the data acquisition phase of the Skin Universe Project (SUP), collecting over 33 million empirical data points in what it calls the largest known dataset of skin microbial interactions.
- Socioeconomic Disparities Tied to HS Diagnoseshttps://practicaldermatology.com/news/socioeconomic-disparities-tied-to-hs-diagnoses/2474703/Patients living in lower socioeconomic neighborhoods are more likely to be diagnosed with hidradenitis suppurativa (HS), according to a new cross-sectional analysis of data from the University of California San Francisco (UCSF) health system.
- Market for Atopic Dermatitis Treatments to Surge Past $22 Billionhttps://practicaldermatology.com/news/market-for-atopic-dermatitis-treatments-to-surge-past-22-billion/2474524/The global atopic dermatitis (AD) market is projected to more than double over the next decade, reaching $22.37 billion by 2034, new research from Polaris Market Research indicates. Driven by an annual growth rate of 8.5%, the